Taking angiotensin-converting enzyme inhibitors during pregnancy: Is it safe?

Canadian Family Physician

Volumn 58, Issue 1, 2012, Pages 49-51

  Al Maawali, Almundher ^a   Walfisch, Asnat ^a   Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ARTICLE; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; FETUS GROWTH; FETUS RISK; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; META ANALYSIS (TOPIC); NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC);

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84856084747     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am J Med 2009;122(10):890-5.
2. James DK, Steer PJ, Weiner CP, Gonik B. High-risk pregnancy management options. London, Engl: Saunders Company Ltd; 1996.
3. Chandiramani M, Shennan A. Hypertensive disorders of pregnancy: a UK-based perspective. Curr Opin Obstet Gynecol 2008;20(2):96-101. (Pubitemid 351498757)
4. Ratnapalan S, Koren G. Taking ACE inhibitors during pregnancy. Is it safe? Can Fam Physician 2002;48:1047-9. (Pubitemid 34823357)
5. Reisenberger K, Egarter C, Sternberger B, Eckenberger P, Eberle E, Weissenbacher ER. Placental passage of angiotensin-converting enzyme inhibitors. Am J Obstet Gynecol 1996;174(5):1450-5. (Pubitemid 26165259)
6. Pryde PG, Sedman AB, Nugent CE, Barr M Jr. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993;3(9):1575-82.
7. Mastrobattista J. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997;21(2):124-34. (Pubitemid 27264001)
8. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82(1):23-8. Epub 2006 Jan 19.
9. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;8;354(23):2443-51.
10. Ray JG, Vermeulen MJ, Koren G. Taking ACE inhibitors during early pregnancy. Is it safe? Can Fam Physician 2007;53:1439-40. (Pubitemid 351194553)
11. Mikhail LN, Walker CK, Mittendorf R. Association between maternal obesity and fetal cardiac malformations in African Americans. J Natl Med Assoc 2002;94(8):695-700.
12. Cedergren MI, Källén BA. Maternal obesity and infant heart defects. Obes Res 2003;11(9):1065-71. (Pubitemid 41151583)
13. Walfisch A, Al-Maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31(6):465-72.
14. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011;31(4):540-5. Epub 2011 Feb 18.
15. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005;112(6):710-2. (Pubitemid 40852836)
16. Malm H, Artama M, Gissler M, Klaukka T, Meriläinen J, Nylander O, et al. First trimester use of ACEinhibitors and risk of major malformations. Reprod Toxicol 2008;26(1):67.
17. Lennestål R, Olausson PO, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65(6):615-25. Epub 2009 Feb 7.
18. Cournot MP, Vial T, Carlier P, Jonville-Bera AP, Alt M, Elefant E, et al. Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study. Drug Saf 2006;29(10):911-1010.
19. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. JAMA 1997;277(15):1193-4.
20. Boix E, Zapater P, Picó A, Moreno O. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005;28(11):1029-31. (Pubitemid 43265771)
21. Maliheh K, Abdorrazagh K, Armen K, Reza S. Angiotensin converting enzyme inhibitors and aortic arch obstructive malformations. Indian J Med Sci 2006;60(10):417-20. (Pubitemid 44507108)
22. Sekine T, Miura K, Takahashi K, Igarashi T. Children's toxicology from bench to bed - drug-induced renal injury (1): the toxic effects of ARB/ACEI on fetal kidney development. J Toxicol Sci 2009;34 Suppl 2:SP245-50.
23. Tabacova S, Little R, Tsong Y, Vega A, Kimmel AC. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003;12(8):633-46. (Pubitemid 38028777)